Efficacy of oral powder compared with chewable tablets for lanthanum carbonate administration in hemodialysis patients

Hemodialysis International

Volumn 17, Issue SUPPL1, 2013, Pages

  Sakurada, Tsutomu ^a   Oishi, Daisuke ^a   Shibagaki, Yugo ^a   Yasuda, Takashi ^a   Kimura, Kenjiro ^a  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Adherence; Chewable tablet; Lanthanum carbonate; Oral powder

Indexed keywords

CALCIUM; LANTHANUM CARBONATE; PARATHYROID HORMONE; PHOSPHORUS;

ADULT; AGED; ARTICLE; CALCIUM BLOOD LEVEL; CHEWABLE TABLET; CLINICAL ARTICLE; COMPARATIVE STUDY; DIABETES MELLITUS; DRUG EFFICACY; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; MALE; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; POWDER; RETROSPECTIVE STUDY; WEIGHT GAIN;

ADHERENCE; CHEWABLE TABLET; LANTHANUM CARBONATE; ORAL POWDER;

ADMINISTRATION, ORAL; AGED; CALCIUM; FEMALE; HUMANS; LANTHANUM; MALE; PHOSPHORUS; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; RETROSPECTIVE STUDIES; TABLETS; TREATMENT OUTCOME;

EID: 84885745394     PISSN: 14927535     EISSN: 15424758     Source Type: Journal    
DOI: 10.1111/hdi.12081     Document Type: Article

References (17)

1. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004; 15:2208-2218.
2. Moe S, Drueke T, Cunningham J, etal. Definition, evaluation, and classification of renal osteodystrophy: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006; 69:1945-1953.
3. Guideline Working Group, Japanese Society for Dialysis Therapy. Clinical practice guideline for the management of secondary hyperparathyroidism in chronic dialysis patients. Ther Apher Dial. 2008; 12:511-522.
4. Reynolds JL, Joannides AJ, Skepper JN, etal. Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: A potential mechanism for accelerated vascular calcification in ESRD. J Am Soc Nephrol. 2004; 15:2857-2867.
5. Nakai S, Akiba T, Kazama J, etal. Effects of serum calcium, phosphorous, and intact parathyroid hormone levels on survival in chronic hemodialysis patients in Japan. Ther Apher Dial. 2008; 12:49-54.
6. Wei M, Taskapan H, Esbaei K, Jassal SV, Bargman JM, Oreopoulos DG. K/DOQI guideline requirements for calcium, phosphate, calcium phosphate product, and parathyroid hormone control in dialysis patients: Can we achieve them? Int Urol Nephrol. 2006; 38:739-743.
7. T S. Lanthanum carbonate group: Multicenter prospective randomized, double-blind comparative study between lanthanum carbonate and calcium carbonate as phosphate binders in Japanese hemodialysis patients with hyperphosphatemia. Clin Nephrol. 2008; 70:404-410.
8. Navaneethan SD, Palmer SC, Craig JC, Elder GJ, Strippoli GF. Benefits and harms of phosphate binders in CKD: A systematic review of randomized controlled trials. Am J Kidney Dis. 2009; 54:619-637.
9. Arenas MD, Rebollo P, Malek T, etal. A comparative study of two new phosphate binders (sevelamer and lanthanum carbonate) in routine clinical practice. J Nephrol. 2010; 23:683-692.
10. Nakai S, Masakane I, Akiba T, etal. Overview of regular dialysis treatment in Japan as of 31 December 2006. Ther Apher Dial. 2008; 12:428-456.
11. Sprague SM. A comparative review of the efficacy and safety of established phosphate binders: Calcium, sevelamer, and lanthanum carbonate. Curr Med Res Opin. 2007; 23:3167-3175.
12. Arenas MD, Malek T, Gil MT, Moledous A, Alvarez-Ude F, Reiq-Ferrer A. Challenge of phosphorus control in hemodialysis patients: A problem of adherence? J Nephrol. 2010; 23:525-534.
13. How PP, Mason DL, Arruda JA, Lau AH. Efficacy of chewed vs. crushed lanthanum on phosphorus binding in healthy volunteers. Clin Nephrol. 2010; 73:370-373.
14. How PP, Anattiwong P, Mason DL, Arruda JA, Lau AH. Phosphate-binding efficacy of crushed vs. chewed lanthanum carbonate in hemodialysis patients. Hemodial Int. 2011; 15:95-99. doi:10.1111/j.1542-4758.2010.00509.x
15. Pierce D, Hossack S, Robinson A, Zhanq P, Martin P. Assessment of pharmacodynamic equivalence and tolerability of lanthanum carbonate oral powder and tablet formulations: A single-center, randomized, open-label, two-period crossover study in healthy subjects. Clin Ther. 2012; 34:1290-1300.
16. Shire Canada Inc. 2012. Product monograph: Fosrenol (lanthanum carbonate hydrate). Available from: http://www.shirecanada.com/en/shire-canada/Forms/AllItems.aspx?RootFolder=http%3a%2f%2fwww%2eshirecanada%2ecom%2fen%2fshire%2dcanada%2fPDF%202013&FolderCTID=0x0120007CE95CE7DC9EEF4E9C3009B195088F60 (accessed date: February 19, 2013).
17. Yang Y, Bykadi S, Carlin AS, Shah RB, Yu LX, Khan MA. Comparative evaluation of the in vitro efficacy of lanthanum carbonate chewable tablets. J Pharm Sci. 2013; 102:1370-1381. doi:10.1002/jps.23454